Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MSc

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]:

Source: Neurology Read More

Previous PostReal-World Study Highlights Immunotherapy Trends and Effectiveness in NMOSD and MOGAD
Next PostMSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MSc

Previous PostReal-World Study Highlights Immunotherapy Trends and Effectiveness in NMOSD and MOGAD

Next PostMSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

Related Posts

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

<![CDATA[TEMPO-4 Extension Analysis: Tavapadon Shows Levodopa-Sparing Potential in Parkinson Disease]]>

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

Categories